Breast cancer risk in relation to the interval between menopause and starting hormone therapy
Background: Although breast cancer risk is greater in users of estrogen-progestin than estrogen-only formulations of menopausal hormonal therapy, reports on their effects have been somewhat inconsistent. We investigated whether the timing of these therapies affected breast cancer incidence. Methods: A total of 1 129 025 postmenopausal UK women provided prospective information on hormonal therapy use and other factors relevant for breast cancer risk. We used Cox regression to estimate adjusted...[Show more]
|Collections||ANU Research Publications|
|Source:||Journal of the National Cancer Institute|
|01_Beral_Breast_cancer_risk_in_relation_2011.pdf||439.6 kB||Adobe PDF||Request a copy|
Items in Open Research are protected by copyright, with all rights reserved, unless otherwise indicated.